J-Code for ThromboGenics' JETREA to Become Effective January 1, 2014

J-Code for ThromboGenics' JETREA toJ-Code for ThromboGenics' JETREA to Become Effective January 1, 2014 PR Newswire LEUVEN, Belgium, December 3, 2013 Permanent J-Code J7316 will lead to streamlined reimbursement of JETREA® in the US ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that CMS (Center for Medicare and Medicaid Services) has published the permanent HCPCS (Healthcare Common Procedure Coding System) code for JETREA ®(ocriplasmin) J7316. The permanent J-Code for JETREA will become effective 1 January 2014. ®The absence of a HCPCS code for JETREA has meant that US physicians have had to manually submit JETREA claims to payers following their use of this novel treatment for symptomatic VMA (vitreomacular adhesion). This has led to delays in reimbursement, and certain inefficiencies in use of financial working capital at a retina practice management level. The permanent J-Code will streamline the reimbursement process for retina practices and instil higher reimbursement confidence. Recent market research conducted by ThromboGenics has highlighted that the lack of a permanent J-Code is ®having an adverse impact on the uptake of JETREA . Dr Patrik De Haes, CEO of ThromboGenics said, "We are extremely ®pleased that the CMS has granted a permanent J-Code for JETREA .